Casma Therapeutics

formerly Casma

Reprogramming autophagy to eliminate diseases that current drugs have failed to target

Cambridge, United States · Founded 2018 · $162.1M raised

Employees
11–50
Founded
2018
Business Model
B2B
Total Funding
$162.1M
Last Round
$46.0M Series CNov 2022
Rounds
4

About

Casma Therapeutics is a biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts, developing targeted therapies that engage the lysosomal and autophagy systems to selectively degrade disease-causing elements. The company's proprietary PHLYT platform reprograms the autophagy pathway to permanently eliminate disease targets inside cells, including aggregated proteins, damaged organelles, and pathogens. Casma's pipeline is focused on neurodegeneration, lysosomal storage disorders, liver disease, muscle disorders, and cancer, with lead program CSM-101 advancing toward development candidate nomination.

Summary

Casma Therapeutics is a Biotech company based in Cambridge, United States, founded in 2018. It has raised $162.1M in total across 4 rounds, most recently a $46.0M Series C round in Nov 2022. Investors include Third Rock Ventures, The Column Group and Amgen.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CNov 2022
$46.0M

Sign up to see all 4 rounds

Series A through Series C — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Casma Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/casma-therapeutics"><img src="https://indexed.vc/api/badge/company/casma-therapeutics" alt="Casma Therapeutics on Indexed.vc" width="260" height="76" /></a>